Análise do papel do índice de imuno-inflamação sistêmica como fator de prognóstico no câncer de mama triplo negativo

Abstract

Breast cancer is the most frequent neoplasm among female patients, as well as the first cause of death in all Brazilian regions, except the North region. The prognosis of this type of cancer will depend on certain aspects, such as the molecular classification, with the triple negative type being the most aggressive modality. Thus, some biomarkers have been used as factors for the assessment of overall breast cancer survival, such as Ki-67, residual cancer burden and, currently, host immune and inflammatory cells are considered “key parts ” for the evaluation of prognosis, such as neutrophils, lymphocytes and platelets. It is important to point out that this evaluation will take place through the Systemic Immuno-Inflammation Index (SII), which is considered a comprehensive hematological parameter. Thus, this dissertation comprises a chapter that has the general objective of analyzing the relationship between the IBS index as a prognosis for patients with triple negative breast cancer, and the specific objectives: 1) Carry out a systematic review with meta-analysis; 2) Correlate Overall Survival (OS) and Disease Free Survival (DFS) with IBS in patients with triple negative breast cancer; 3) Evaluate the demographic and clinical-pathological characteristics. In chapter 1, a systematic review was carried out with a meta-analysis recorded in the PROPERO database. The search strategy was performed on six databases, including the gray literature. After applying all eligibility criteria, 03 studies were selected. The outcomes of Overall Survival and Disease Free Survival were evaluated, suggesting that IBS is a promising indicator for the prognosis of triple negative breast cancer. However, there is still a need for further studies on the subject.